

Stephen J Gange

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1361514/publications.pdf>

Version: 2024-02-01

263
papers

23,495
citations

11608

70
h-index

8599

146
g-index

269
all docs

269
docs citations

269
times ranked

21877
citing authors

#	ARTICLE	IF	CITATIONS
1	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. <i>Nature Medicine</i> , 1999, 5, 512-517.	15.2	1,962
2	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. <i>Nature Medicine</i> , 2003, 9, 727-728.	15.2	1,482
3	Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 223-243.	2.1	1,374
4	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	1.1	1,111
5	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	13.9	986
6	Competing Risk Regression Models for Epidemiologic Data. <i>American Journal of Epidemiology</i> , 2009, 170, 244-256.	1.6	984
7	Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 1999, 73, 10489-10502.	1.5	875
8	The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench. <i>Vaccine Journal</i> , 2005, 12, 1013-1019.	3.2	474
9	Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance. <i>Clinical Infectious Diseases</i> , 2003, 37, 1112-1118.	2.9	397
10	Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9403-9408.	3.3	393
11	Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in a Randomized Clinical Trial in He Zuo Township, Qidong, People's Republic of China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2605-2613.	1.1	287
12	T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2011, 203, 452-463.	1.9	281
13	Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 14601-14606.	3.3	273
14	Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults. <i>Clinical Infectious Diseases</i> , 2015, 60, 627-638.	2.9	235
15	Driving Status and Risk of Entry Into Long-Term Care in Older Adults. <i>American Journal of Public Health</i> , 2006, 96, 1254-1259.	1.5	231
16	Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. <i>Aids</i> , 2008, 22, 1615-1624.	1.0	226
17	Association of Cigarette Smoking With HIV Prognosis Among Women in the HAART Era: A Report From the Women's Interagency HIV Study. <i>American Journal of Public Health</i> , 2006, 96, 1060-1065.	1.5	215
18	Cohort Profile: The Women's Interagency HIV Study (WIHS). <i>International Journal of Epidemiology</i> , 2018, 47, 393-394i.	0.9	214

#	ARTICLE	IF	CITATIONS
19	Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1062-1071.	3.0	204
20	Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 50, 912-919.	2.9	202
21	Predictors of proteinuria and renal failure among women with HIV infection. <i>Kidney International</i> , 2002, 61, 195-202.	2.6	199
22	Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women. <i>Clinical Infectious Diseases</i> , 2007, 45, 1074-1081.	2.9	193
23	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 149-163.	0.9	188
24	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	2.9	187
25	Invasive Cervical Cancer Risk Among HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 405-413.	0.9	184
26	C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression. <i>Archives of Internal Medicine</i> , 2006, 166, 64.	4.3	178
27	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	0.9	176
28	Random survival forests for competing risks. <i>Biostatistics</i> , 2014, 15, 757-773.	0.9	176
29	Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication. <i>Journal of Virology</i> , 2002, 76, 4138-4144.	1.5	171
30	Association between Renal Disease and Outcomes among HIV-Infected Women Receiving or Not Receiving Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1199-1206.	2.9	169
31	Stability of the Latent Reservoir for HIV-1 in Patients Receiving Valproic Acid. <i>Journal of Infectious Diseases</i> , 2007, 195, 833-836.	1.9	169
32	DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1. <i>Transplantation</i> , 1996, 61, 1581-1586.	0.5	153
33	Association of Race and Gender With HIV-1 RNA Levels and Immunologic Progression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 24, 218-226.	0.9	149
34	Increases in Human Papillomavirus Detection During Early HIV Infection Among Women in Zimbabwe. <i>Journal of Infectious Diseases</i> , 2011, 203, 1182-1191.	1.9	149
35	Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. <i>Journal of the International AIDS Society</i> , 2020, 23, e25484.	1.2	148
36	Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. <i>Gastroenterology</i> , 2004, 127, S310-S318.	0.6	144

#	ARTICLE	IF	CITATIONS
37	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	2.9	142
38	Regulatory CD4 ⁺ T Cells Recognize Major Histocompatibility Complex Class II Molecule-Restricted Peptide Epitopes of Apolipoprotein B. <i>Circulation</i> , 2018, 138, 1130-1143.	1.6	140
39	Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. <i>Quality of Life Research</i> , 2000, 9, 55-63.	1.5	132
40	Retention Among North American HIV-Infected Persons in Clinical Care, 2000-2008. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 356-362.	0.9	131
41	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1230-1238.	2.9	131
42	Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. <i>Aids</i> , 2003, 17, 1941-1951.	1.0	129
43	Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1070-1076.	3.0	127
44	Patterns and Predictors of Changes in Adherence to Highly Active Antiretroviral Therapy: Longitudinal Study of Men and Women. <i>Clinical Infectious Diseases</i> , 2007, 45, 1377-1385.	2.9	123
45	Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure. <i>Journal of Virology</i> , 2002, 76, 9481-9492.	1.5	119
46	Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. <i>Aids</i> , 2005, 19, 2009-2018.	1.0	117
47	T cell activation predicts carotid artery stiffness among HIV-infected women. <i>Atherosclerosis</i> , 2011, 217, 207-213.	0.4	117
48	Atazanavir Concentration in Hair Is the Strongest Predictor of Outcomes on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 52, 1267-1275.	2.9	116
49	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. <i>Journal of Infectious Diseases</i> , 2016, 214, 862-872.	1.9	116
50	The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. <i>Aids</i> , 2011, 25, 1823-1832.	1.0	112
51	HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis. <i>Clinical Infectious Diseases</i> , 2015, 61, 640-650.	2.9	112
52	Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 179-187.	0.9	111
53	Factors Associated with Preclinical Disability and Frailty among HIV-Infected and HIV-Uninfected Women in the Era of cART. <i>Journal of Women's Health</i> , 2009, 18, 1965-1974.	1.5	110
54	Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 568-576.	0.9	110

#	ARTICLE	IF	CITATIONS
55	Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART. <i>Journal of Dental Research</i> , 2004, 83, 145-150.	2.5	107
56	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. <i>Annals of Internal Medicine</i> , 2012, 157, 325.	2.0	106
57	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
58	Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 205, 1788-1796.	1.9	100
59	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	2.1	94
60	Protease inhibitor levels in hair strongly predict virologic response to treatment. <i>Aids</i> , 2009, 23, 471-478.	1.0	92
61	Virologic and immunologic response to HAART, by age and regimen class. <i>Aids</i> , 2010, 24, 2469-2479.	1.0	92
62	Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. <i>Hepatology</i> , 2010, 51, 1514-1522.	3.6	90
63	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	2.9	90
64	The parametric g-computation formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. <i>Statistics in Medicine</i> , 2012, 31, 2000-2009.	0.8	89
65	Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men. <i>Journal of Infectious Diseases</i> , 2017, 215, 1352-1361.	1.9	87
66	Marginal and Mixed-Effects Models in the Analysis of Human Papillomavirus Natural History Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 159-169.	1.1	82
67	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , 2010, 376, 340-345.	6.3	82
68	Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. <i>Aids</i> , 2005, 19, 1885-1896.	1.0	79
69	Trajectories of Injection Drug Use Over 20 Years (1988-2008) in Baltimore, Maryland. <i>American Journal of Epidemiology</i> , 2011, 173, 829-836.	1.6	77
70	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	0.7	73
71	Changes in Sexual Behavior Among HIV-Infected Women After Initiation of HAART. <i>American Journal of Public Health</i> , 2004, 94, 1141-1146.	1.5	71
72	The Prognostic Importance of Changes in CD4 ⁺ Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2004, 140, 256.	2.0	69

#	ARTICLE	IF	CITATIONS
73	The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 537-44.	0.9	69
74	Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus. <i>American Journal of Epidemiology</i> , 2000, 152, 923-933.	1.6	68
75	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	2.9	67
76	Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. <i>Journal of Epidemiology and Community Health</i> , 2002, 56, 153-159.	2.0	66
77	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	2.9	65
78	Common clinical conditions “ age, low BMI, ritonavir use, mild renal impairment “ affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. <i>Aids</i> , 2014, 28, 59-66.	1.0	61
79	Quantification of Sulforaphane Mercapturic Acid Pathway Conjugates in Human Urine by High-Performance Liquid Chromatography and Isotope-Dilution Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2008, 21, 1991-1996.	1.7	60
80	Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV Study*. <i>Aids</i> , 2000, 14, 863-870.	1.0	59
81	Slow Human Immunodeficiency Virus Type 1 Evolution in Viral Reservoirs in Infants Treated with Effective Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 381-390.	0.5	59
82	A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 206, 1453-1461.	1.9	59
83	Serum Albumin Is a Powerful Predictor of Survival Among HIV-1-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 66-73.	0.9	58
84	Outcomes After Treatment of Cervical Intraepithelial Neoplasia Among Women With HIV. <i>Journal of Lower Genital Tract Disease</i> , 2007, 11, 90-97.	0.9	58
85	Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. <i>Aids</i> , 2010, 24, 1657-1665.	1.0	58
86	The effect of neighborhood deprivation and residential relocation on long-term injection cessation among injection drug users (IDUs) in Baltimore, Maryland. <i>Addiction</i> , 2011, 106, 1966-1974.	1.7	58
87	Impact of Inversion of the CD4/CD8 Ratio on the Natural History of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 620-626.	0.9	57
88	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	2.9	55
89	Generating Multivariate Categorical Variates Using the Iterative Proportional Fitting Algorithm. <i>American Statistician</i> , 1995, 49, 134-138.	0.9	54
90	Potential Cardiovascular Disease Risk Markers Among HIV-Infected Women Initiating Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 359-368.	0.9	54

#	ARTICLE	IF	CITATIONS
91	Interval and Clinical Cohort Studies: Epidemiological Issues. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 769-776.	0.5	53
92	Prevalence of Clinical Symptoms Associated with Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study. <i>Clinical Infectious Diseases</i> , 2004, 39, 717-724.	2.9	52
93	Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. <i>Aids</i> , 2000, 14, 1155-1161.	1.0	50
94	Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. <i>AIDS Patient Care and STDs</i> , 2017, 31, 129-144.	1.1	50
95	Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. <i>Carcinogenesis</i> , 2003, 24, 1919-1928.	1.3	49
96	Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1300-1307.	1.1	49
97	Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. <i>Aids</i> , 2000, 14, 754-756.	1.0	49
98	Assessing the effect of HAART on change in quality of life among HIV-infected women. <i>AIDS Research and Therapy</i> , 2006, 3, 6.	0.7	48
99	Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. <i>Journal of General Virology</i> , 2005, 86, 2709-2720.	1.3	47
100	Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. <i>Addiction</i> , 2011, 106, 1437-1445.	1.7	47
101	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. <i>PLoS ONE</i> , 2016, 11, e0146119.	1.1	47
102	Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). <i>Oral Diseases</i> , 2009, 15, 52-60.	1.5	46
103	Disparities among US states in HIV-related mortality in persons with HIV infection, 2001-2007. <i>Aids</i> , 2012, 26, 95-103.	1.0	46
104	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	2.1	46
105	Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. <i>Clinical Infectious Diseases</i> , 2004, 38, 1167-1174.	2.9	45
106	Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. <i>International Journal of Epidemiology</i> , 2018, 47, 654-668.	0.9	45
107	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
108	Effectiveness of highly-active antiretroviral therapy by race/ethnicity. <i>Aids</i> , 2006, 20, 1531-1538.	1.0	43

#	ARTICLE	IF	CITATIONS
109	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	1.9	43
110	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 62-72.	0.9	43
111	Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0129100.	1.1	43
112	Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. <i>Carcinogenesis</i> , 1995, 16, 1769-1773.	1.3	42
113	Disclosure of Complementary and Alternative Medicine Use to Health Care Providers among HIV-Infected Women. <i>AIDS Patient Care and STDs</i> , 2009, 23, 965-971.	1.1	42
114	Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. <i>Aids</i> , 2012, 26, 599-607.	1.0	42
115	The Effect of Highly Active Antiretroviral Therapy on Dermatologic Disease in a Longitudinal Study of HIV Type 1-Infected Women. <i>Clinical Infectious Diseases</i> , 2004, 38, 579-584.	2.9	39
116	Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. <i>American Journal of Epidemiology</i> , 2017, 185, 869-878.	1.6	38
117	Dependence of the hazard of AIDS on markers. <i>Aids</i> , 1997, 11, 217-228.	1.0	37
118	<i>CYP1A1</i> Genotype Modifies the Impact of Smoking on Effectiveness of HAART Among Women. <i>AIDS Education and Prevention</i> , 2009, 21, 81-93.	0.6	37
119	The Impact of Kidney Function at Highly Active Antiretroviral Therapy Initiation on Mortality in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 217-220.	0.9	37
120	FRAILTY AND CONSTELLATIONS OF FACTORS IN AGING HIV-INFECTED AND UNINFECTED WOMEN - THE WOMEN'S INTERAGENCY HIV STUDY. <i>Journal of Frailty & Aging</i> , 2016, 5, 1-6.	0.8	37
121	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw804.	2.9	37
122	Methodological Issues for Biomarkers and Intermediate Outcomes in Cohort Studies. <i>Epidemiologic Reviews</i> , 1998, 20, 29-42.	1.3	36
123	CC Chemokine Receptor 5 Genotype and Susceptibility to Transmission of Human Immunodeficiency Virus Type 1 in Women. <i>Journal of Infectious Diseases</i> , 2003, 187, 569-575.	1.9	36
124	Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. <i>Retrovirology</i> , 2009, 6, 54.	0.9	36
125	Hormonal Contraceptive Use and the Effectiveness of Highly Active Antiretroviral Therapy. <i>American Journal of Epidemiology</i> , 2005, 161, 881-890.	1.6	35
126	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33

#	ARTICLE	IF	CITATIONS
127	Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication <i>In Vitro</i> and Modulate HIV Restriction Factor Expression. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
128	Sequential monitoring of clinical trials with correlated responses. <i>Biometrika</i> , 1996, 83, 157-167.	1.3	32
129	Association of Race and Gender With HIV-1 RNA Levels and Immunologic Progression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 218-226.	0.9	32
130	Herpes simplex virus infection in women in the WIHS: Epidemiology and effect of antiretroviral therapy on clinical manifestations. <i>Aids</i> , 2006, 20, 1051-1058.	1.0	32
131	Age and Racial/Ethnic Differences in the Prevalence of Reported Symptoms in Human Immunodeficiency Virus-Infected Persons on Antiretroviral Therapy. <i>Journal of Pain and Symptom Management</i> , 2009, 38, 197-207.	0.6	32
132	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019, 188, 2097-2109.	1.6	32
133	Host APOL1 genotype is independently associated with proteinuria in HIV infection. <i>Kidney International</i> , 2013, 84, 834-840.	2.6	31
134	Prevalence and predictors of skin disease in the Women's Interagency HIV Study (WIHS). <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 785-788.	0.6	30
135	Longitudinal Relationships Between Use of Highly Active Antiretroviral Therapy and Satisfaction With Care Among Women Living With HIV/AIDS. <i>American Journal of Public Health</i> , 2006, 96, 1044-1051.	1.5	29
136	Acquisition of New Sexual Partners Among Women With HIV Infection: Patterns of Disclosure and Sexual Behavior within New Partnerships. <i>AIDS Education and Prevention</i> , 2007, 19, 151-159.	0.6	29
137	A comparison of methods for correlated ordinal measures with ophthalmic applications. <i>Statistics in Medicine</i> , 1995, 14, 1961-1974.	0.8	28
138	Anti-HIV Type 1 Memory Cytotoxic T Lymphocyte Responses Associated with Changes in CD4 ⁺ T Cell Numbers in Progression of HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1423-1433.	0.5	28
139	Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10848-10853.	3.3	28
140	Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1794-1801.	3.9	28
141	Strong Agreement of Nationally Recommended Retention Measures from the Institute of Medicine and Department of Health and Human Services. <i>PLoS ONE</i> , 2014, 9, e111772.	1.1	27
142	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	2.9	27
143	Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. <i>Aids</i> , 2003, 17, 119-121.	1.0	26
144	Elevated NT-pro-BNP Levels Are Associated with Comorbidities among HIV-Infected Women. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 997-1004.	0.5	26

#	ARTICLE	IF	CITATIONS
145	Evidence that anoreceptive intercourse with ejaculate exposure is associated with rapid CD4 cell loss. <i>Aids</i> , 2000, 14, 707-715.	1.0	25
146	Factors Associated with Incident Self-Reported AIDS among Women Enrolled in the Women's Interagency HIV Study (WIHS). <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1105-1111.	0.5	25
147	Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. <i>AIDS Research and Therapy</i> , 2007, 4, 12.	0.7	25
148	The Effect of HAART on HIV RNA Trajectory Among Treatment-naïve Men and Women. <i>Epidemiology</i> , 2010, 21, S25-S34.	1.2	25
149	Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. <i>AIDS Patient Care and STDs</i> , 2017, 31, 447-454.	1.1	25
150	Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 664371.	2.2	25
151	Title is missing!. <i>AIDS and Behavior</i> , 2001, 5, 353-361.	1.4	24
152	Incidence of Violence Against HIV-Infected and Uninfected Women: Findings from the HIV Epidemiology Research (HER) Study. <i>Journal of Urban Health</i> , 2002, 79, 512-524.	1.8	24
153	High-Risk Behavior and Potential Transmission of Drug-Resistant HIV Among Injection Drug Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 503-510.	0.9	24
154	Echoluency of the Carotid Artery Intima-Media Complex and Intima-Media Thickness Have Different Cardiovascular Risk Factor Relationships: The Women's Interagency HIV Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	24
155	Ocular renin angiotensin: EM immunocytochemical localization of prorenin. <i>Current Eye Research</i> , 1993, 12, 945-950.	0.7	23
156	Prevalence and Correlates of Highly Active Antiretroviral Therapy Switching in the Women's Interagency HIV Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 495-503.	0.9	23
157	Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry. <i>Statistics in Medicine</i> , 2011, 30, 654-665.	0.8	23
158	Prevalence and Correlates of Highly Active Antiretroviral Therapy Switching in the Women's Interagency HIV Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 495-503.	0.9	22
159	Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. <i>Aids</i> , 2003, 17, 2035-2044.	1.0	22
160	Reduced fertility among HIV-infected women associated with viral load in Rakai district, Uganda. <i>International Journal of STD and AIDS</i> , 2006, 17, 842-846.	0.5	22
161	Consistency of Initial Antiretroviral Therapy With HIV Treatment Guidelines in a US Cohort of HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 377-383.	0.9	22
162	Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 482-491.	0.9	22

#	ARTICLE	IF	CITATIONS
163	Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. <i>American Journal of Epidemiology</i> , 2015, 182, 952-960.	1.6	22
164	Carotid artery atherosclerosis is associated with mortality in HIV-positive women and men. <i>Aids</i> , 2018, 32, 2393-2403.	1.0	22
165	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	2.9	22
166	The Relationship between Virus Load Response to Highly Active Antiretroviral Therapy and Change in CD4 Cell Counts: A Report from the Women's Interagency HIV Study. <i>Journal of Infectious Diseases</i> , 2000, 182, 1527-1530.	1.9	21
167	Dissatisfaction with medical care among women with HIV: Dimensions and associated factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2003, 15, 451-462.	0.6	21
168	Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 245-248.	1.1	21
169	From Smallpox to Big Data: The Next 100 Years of Epidemiologic Methods. <i>American Journal of Epidemiology</i> , 2016, 183, 423-426.	1.6	21
170	Individual Variation in CD4 Cell Count Trajectory among Human Immunodeficiency Virus-infected Men and Women on Long-term Highly Active Antiretroviral Therapy: An Application using a Bayesian Random Change-Point Model. <i>American Journal of Epidemiology</i> , 2005, 162, 787-797.	1.6	19
171	Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. <i>Sexually Transmitted Infections</i> , 2008, 84, 306-311.	0.8	19
172	Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection Drug Using Women. <i>Sexually Transmitted Diseases</i> , 2009, 36, 149-156.	0.8	19
173	Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. <i>Virology Journal</i> , 2010, 7, 328.	1.4	19
174	Human Leukocyte Antigen Genotype and Risk of HIV Disease Progression before and after Initiation of Antiretroviral Therapy. <i>Journal of Virology</i> , 2011, 85, 10826-10833.	1.5	19
175	Longitudinal Assessment of de Novo T Cell Production in Relation to HIV-Associated T Cell Homeostasis Failure. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 501-507.	0.5	18
176	Correlates of CD4+ and CD8+ Lymphocyte Counts in High-Risk Immunodeficiency Virus (HIV)-Seronegative Women enrolled in the Women's Interagency HIV Study (WIHS). <i>Human Immunology</i> , 2007, 68, 342-349.	1.2	18
177	Evaluating competing adverse and beneficial outcomes using a mixture model. <i>Statistics in Medicine</i> , 2008, 27, 4313-4327.	0.8	18
178	The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women. <i>Journal of Infectious Diseases</i> , 2011, 203, 1807-1814.	1.9	18
179	Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 1579-1584.	1.0	17
180	Identifying the appropriate comparison group for HIV-infected individuals. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 379-385.	1.5	17

#	ARTICLE	IF	CITATIONS
181	Superior cervical ganglionectomy in monkeys: Aqueous humor dynamics and their responses to drugs. <i>Experimental Eye Research</i> , 1995, 60, 575-584.	1.2	16
182	Longitudinal Patterns of HIV Type 1 RNA among Individuals with Late Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1223-1229.	0.5	16
183	Outcome After Negative Colposcopy Among Human Immunodeficiency Virus-Infected Women With Borderline Cytologic Abnormalities. <i>Obstetrics and Gynecology</i> , 2005, 106, 525-532.	1.2	16
184	Single cell transcriptomics and TCR reconstruction reveal CD4 T cell response to MHC-II-restricted APOB epitope in human cardiovascular disease. , 2022, 1, 462-475.		16
185	Interleukin 10 Responses Are Associated With Sustained CD4 T-Cell Counts in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 780-789.	1.9	15
186	Predicting death over 8 years in a prospective cohort of HIV-infected women: the Women's Interagency HIV Study. <i>BMJ Open</i> , 2017, 7, e013993.	0.8	15
187	Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. <i>Preventive Medicine</i> , 2010, 50, 223-229.	1.6	14
188	Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. <i>Hepatology</i> , 2012, 56, 1699-1705.	3.6	14
189	A critical epidemiological review of cardiovascular disease risk in HIV-infected adults: the importance of the HIV-uninfected comparison group, confounding, and competing risks. <i>HIV Medicine</i> , 2013, 14, 191-192.	1.0	14
190	Computer-aided assessment of diagnostic images for epidemiological research. <i>BMC Medical Research Methodology</i> , 2009, 9, 74.	1.4	13
191	Increased gonorrhoea and chlamydia testing did not increase case detection in an HIV clinical cohort 1999-2007. <i>Sexually Transmitted Infections</i> , 2011, 87, 469-475.	0.8	13
192	The Changing Science of HIV Epidemiology in the United States. <i>American Journal of Epidemiology</i> , 2019, 188, 2061-2068.	1.6	13
193	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. <i>Clinical Infectious Diseases</i> , 2019, 68, 795-802.	2.9	13
194	Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 620-5.	0.9	13
195	Vitamin A deficiency and genital viral burden in women infected with HIV-1. <i>Lancet, The</i> , 2002, 359, 1210-1212.	6.3	12
196	Teaching Epidemiologic Methods. <i>Epidemiology</i> , 2008, 19, 353-356.	1.2	12
197	An instrumental variables evaluation of the effect of antidepressant use on employment among HIV-infected women using antiretroviral therapy in the United States: 1996-2004. <i>Health Economics (United Kingdom)</i> , 2010, 19, 173-188.	0.8	12
198	Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus. <i>Genes and Immunity</i> , 2013, 14, 330-335.	2.2	12

#	ARTICLE	IF	CITATIONS
199	Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design. <i>AIDS Research and Treatment</i> , 2015, 2015, 1-11.	0.3	12
200	Examining the Relationships Between Experienced and Anticipated Stigma in Health Care Settings, Patient-Provider Race Concordance, and Trust in Providers Among Women Living with HIV. <i>AIDS Patient Care and STDs</i> , 2021, 35, 441-448.	1.1	12
201	Evaluation of Human Immunodeficiency Virus Biomarkers. <i>Epidemiology</i> , 2009, 20, 664-672.	1.2	11
202	Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. <i>Atherosclerosis</i> , 2012, 225, 408-411.	0.4	11
203	Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). <i>PLoS ONE</i> , 2017, 12, e0188725.	1.1	11
204	Mind the gap: observation windows to define periods of event ascertainment as a quality control method for longitudinal electronic health record data. <i>Annals of Epidemiology</i> , 2019, 33, 54-63.	0.9	11
205	Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis. <i>Cardiovascular Research</i> , 2019, 115, 1029-1040.	1.8	11
206	Clinical Reactivations of Herpes Simplex Virus Type 2 Infection and Human Immunodeficiency Virus Disease Progression Markers. <i>PLoS ONE</i> , 2010, 5, e9973.	1.1	11
207	Genotypic Resistance and Immunologic Outcomes Among HIV-1-Infected Women With Viral Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 68-74.	0.9	10
208	Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women. <i>Aids</i> , 2007, 21, 1933-1941.	1.0	10
209	Retrospective Mortality Study Among Employees Occupationally Exposed to Toner. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 1035-1041.	0.9	10
210	Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study. <i>International Journal of STD and AIDS</i> , 2011, 22, 273-277.	0.5	10
211	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. <i>Annals of Epidemiology</i> , 2017, 27, 783-789.e2.	0.9	10
212	Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. <i>Pharmacogenomics Journal</i> , 2018, 18, 245-250.	0.9	10
213	PARAMETRIC MODELS TO ASSESS TRACKING OF CATEGORICAL HIGH-RISK SEXUAL BEHAVIOUR FOR HIV INFECTION. , 1996, 15, 2323-2336.		9
214	Associations of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3 with HIV Disease Progression in Women. <i>Journal of Infectious Diseases</i> , 2008, 197, 319-327.	1.9	9
215	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	1.6	9
216	Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009. <i>PLoS ONE</i> , 2013, 8, e78952.	1.1	9

#	ARTICLE	IF	CITATIONS
217	Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study. <i>Aids</i> , 2019, 33, 357-359.	1.0	9
218	The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injuryâ€”The Womenâ€™s Interagency HIV Study. <i>PLoS ONE</i> , 2017, 12, e0181004.	1.1	9
219	AIDS Onset at High CD4+Cell Levels Is Associated with High HIV Load. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 103-107.	0.5	8
220	Application of caseâ€“crossover and caseâ€“timeâ€“control study designs in analyses of time-varying predictors of T-cell homeostasis failure. <i>Annals of Epidemiology</i> , 2005, 15, 137-144.	0.9	8
221	Systemic Cytokine Levels Do Not Predict CD4+ T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw025.	0.4	8
222	Classical monocyte transcriptomes reveal significant anti-inflammatory statin effect in women with chronic HIV. <i>Cardiovascular Research</i> , 2021, 117, 1166-1177.	1.8	8
223	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2334-e2337.	2.9	8
224	Patient Health Literacy and Communication with Providers Among Women Living with HIV: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2022, 26, 1422-1430.	1.4	8
225	CCR2 Genotype and Disease Progression in a Treated Population of HIV Type 1-Infected Women. <i>Clinical Infectious Diseases</i> , 2004, 39, 861-865.	2.9	7
226	Patterns, Predictors, and Consequences of Initial Regimen Type among HIV-Infected Women Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 305-312.	2.9	7
227	Lung Function in Women With and Without Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, e727-e735.	2.9	7
228	Methods for the Analysis of Continuous Biomarker Assay Data With Increased Sensitivity. <i>Epidemiology</i> , 2004, 15, 724-732.	1.2	6
229	Combined analysis of retrospective and prospective occurrences in cohort studies: HIV-1 serostatus and incident pneumonia. <i>International Journal of Epidemiology</i> , 2006, 35, 1442-1446.	0.9	6
230	Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. <i>AIDS Research and Therapy</i> , 2009, 6, 13.	0.7	6
231	Relationship of Injection Drug Use, Antiretroviral Therapy Resistance, and Genetic Diversity in the HIV-1 pol Gene. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 381-389.	0.9	6
232	Treatment-related changes in serum lipids and inflammation. <i>Aids</i> , 2013, 27, 1516-1519.	1.0	6
233	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. <i>PLoS ONE</i> , 2015, 10, e0138827.	1.1	6
234	Association of a 3â€² untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfecting women. <i>Aids</i> , 2017, 31, 2483-2492.	1.0	6

#	ARTICLE	IF	CITATIONS
235	History of Incarceration Among Women with HIV: Impact on Prognosis and Mortality. <i>Journal of Women's Health</i> , 2019, 28, 1083-1093.	1.5	6
236	Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women. <i>Aids</i> , 2014, 28, 1815-1823.	1.0	5
237	Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4483.	0.4	5
238	Elevated Microparticle Tissue Factor Activity Is Associated With Carotid Artery Plaque in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 36-43.	0.9	5
239	Prevalence and correlates of restless legs syndrome in men living with HIV. <i>PLoS ONE</i> , 2021, 16, e0258139.	1.1	5
240	The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. <i>Aids</i> , 2008, 22, 527-531.	1.0	4
241	Elevated Caspase-3 Expression and T-Cell Activation in Elite Suppressors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 110-111.	0.9	4
242	Seroincidence of 2009 H1N1 infection in HIV-infected and HIV-uninfected women prior to vaccine availability. <i>Aids</i> , 2011, 25, 1229-1232.	1.0	4
243	A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfecting women. <i>PLoS ONE</i> , 2021, 16, e0247277.	1.1	4
244	T-cell immune dysregulation and mortality in women with HIV. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	4
245	Estimation and inference on correlations between biomarkers with repeated measures and left-censoring due to minimum detection levels. <i>Statistics in Medicine</i> , 2012, 31, 2275-2289.	0.8	3
246	Antiretroviral-Treated HIV-Infected Women Have Similar Long-Term Kidney Function Trajectories as HIV-Uninfected Women. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 755-760.	0.5	3
247	Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	3
248	Brief Report: Subclinical Carotid Artery Atherosclerosis Is Associated With Increased Expression of Peripheral Blood IL-32 Isoforms Among Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 186-191.	0.9	3
249	Screening HIV-positive pregnant women for antiretroviral therapy: utility of self-reported symptoms. <i>International Journal of STD and AIDS</i> , 2006, 17, 112-115.	0.5	2
250	Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study. <i>AIDS Research and Therapy</i> , 2010, 7, 25.	0.7	2
251	Assessment of Different Classification Schemes for Identification of Diastolic Dysfunction in the Women's Interagency HIV Study. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 547-548.	1.2	2
252	Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 315-318.	2.3	2

#	ARTICLE	IF	CITATIONS
253	Restriction of HIV-1 Infection in Sickle Cell Trait. <i>Blood Advances</i> , 2021, 5, 4922-4934.	2.5	2
254	A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 949-956.	2.3	1
255	Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval—Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2019, 39, 899-911.	1.2	1
256	12S Sequential monitoring of clinical trials with correlated categorical data. <i>Contemporary Clinical Trials</i> , 1994, 15, 39-40.	2.0	0
257	Definition of proteinuria among women with HIV infection. <i>Kidney International</i> , 2004, 65, 1519.	2.6	0
258	Resultados clínicos tras el tratamiento de la neoplasia cervical intraepitelial en mujeres con VIH. <i>Journal of Lower Genital Tract Disease</i> , 2008, 1, 27-35.	0.9	0
259	BMI <22.5 and >25 predicted higher overall mortality in adults. <i>Evidence-Based Medicine</i> , 2009, 14, 152-152.	0.6	0
260	P728...Correlates of syphilis in women living with and without HIV in the US women's interagency HIV study (WIHS)., 2019, , .		0
261	Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women's Interagency HIV Study (1994-2015). <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2020-054674.	0.8	0
262	Control of HIV-1 Infection By Ferroportin Q248H Mutation. <i>Blood</i> , 2019, 134, 953-953.	0.6	0
263	Parametric models for studying time to antiretroviral resistance associated with illicit drug use. <i>Wisconsin Medical Journal</i> , 2009, 108, 266-8.	0.3	0